Allakos (ALLK) Q1 2025 earnings summary

Executive summary

• Entered into a Merger Agreement with Concentra Biosciences for a $0.33/share cash tender offer, expected to close in May 2025 if conditions are met.

• Discontinued development of lead candidate AK006 after negative Phase 1 results; initiated a 75% workforce reduction and strategic alternatives review.

• Net loss for Q1 2025 was $26.2 million, a significant improvement from $71.1 million in Q1 2024, primarily due to lower R&D costs and absence of impairment charges.

• Cash, cash equivalents, and investments totaled $55.2 million as of March 31, 2025, expected to fund operations for at least 12 months.

Financial highlights

• Q1 2025 net loss: $26.2 million vs. $71.1 million in Q1 2024; basic and diluted net loss per share: $0.29 vs. $0.81.

• Research and development expenses decreased to $13.5 million from $34.8 million year-over-year, reflecting lower clinical and manufacturing costs.

• General and administrative expenses increased to $13.2 million from $10.9 million, mainly due to costs associated with facility exit.

• No impairment charges in Q1 2025; Q1 2024 included a $27.3 million impairment of long-lived assets.

• Interest income declined to $0.7 million from $2.0 million due to lower investment balances.

Outlook and guidance

• Cash and investments expected to fund operations for at least the next 12 months.

• If the merger is not completed, the board may pursue dissolution and liquidation.

• No new research or clinical programs initiated; focus remains on strategic alternatives.